{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:13:07Z","timestamp":1758039187596,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ad.2018.10.025","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:08:47Z","timestamp":1577142527000},"page":"161-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["FR-Cemiplimab, primer f\u00e1rmaco aprobado para el tratamiento del carcinoma cut\u00e1neo de c\u00e9lulas escamosas metast\u00e1sico o irresecable"],"prefix":"10.1016","volume":"111","author":[{"given":"D.","family":"Morgado-Carrasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Bosch-Amate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Fust\u00e0-Novell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Giavedoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2018.10.025_bib0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ad.2011.12.019","article-title":"Carcinoma epidermoide cut\u00e1neo: definiendo la variante de alto riesgo","volume":"104","author":"Martorell-Calatayud","year":"2013","journal-title":"Actas Dermo-Sifiliog."},{"key":"10.1016\/j.ad.2018.10.025_bib0035","unstructured":"Approved Drugs - FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma [Internet] [consultado 11 Oct 2018]. Disponible en: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm622251.htm"},{"key":"10.1016\/j.ad.2018.10.025_bib0040","unstructured":"Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies - Full Text View - ClinicalTrials.gov [Internet] [consultado 12 Oct 2018]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02383212"},{"key":"10.1016\/j.ad.2018.10.025_bib0045","unstructured":"Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov [Internet] [consultado 12 Oct 2018]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02760498"},{"key":"10.1016\/j.ad.2018.10.025_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019303692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019303692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:09:57Z","timestamp":1757552997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731019303692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0001731019303692"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2018.10.025","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FR-Cemiplimab, primer f\u00e1rmaco aprobado para el tratamiento del carcinoma cut\u00e1neo de c\u00e9lulas escamosas metast\u00e1sico o irresecable","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2018.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}